The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: A systematic review and meta-analysis

Asian Journal of Andrology

Volumn 16, Issue 3, 2014, Pages 487-492

  Luo, Yong ^a   Gou, Xin ^a   Huang, Peng ^a   Mou, Chan ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Meta analysis; PCA3; Prostate cancer; Repeat biopsy; Systematic review

Indexed keywords

PROSTATE ANTIGEN; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; PROSTATE CANCER ANTIGEN 3, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; PREDICTIVE VALUE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); URINALYSIS; AGED; BIOPSY; MALE; META ANALYSIS; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS; URINE;

AGED; ANTIGENS, NEOPLASM; BIOPSY; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84900493843     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.125390     Document Type: Article

References (39)

1. Siegel R Naishadham D Jemal A. Cancer statistics 2012. CA Cancer J Clin 2012; 62: 10-29
2. Matlaga BR Eskew LA McCullough DL. Prostate biopsy: Indications and technique. J Urol 2003; 169: 12-9
3. Raja J Ramachandran N Munneke G Patel U. Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer. Clin Radiol 2006; 61: 142-53
4. Heidenreich A Aus G Bolla M Joniau S Matveev VB et al. European Association of Urology. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80
5. Bussemakers MJ van Bokhoven A Verhaegh GW Smit FP Karthaus HF et al. DD3: New prostate-specific gene highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975-9
6. Hessels D Klein Gunnewiek JM van Oort I Karthaus HF van Leenders GJ et al. DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 8-15
7. Schalken J. Interview with Jack Schalken: PCA3 and its use as a diagnostic test in prostate cancer. Interview by Christine McKillop. Eur Urol 2006; 50: 153-4
8. Crawford ED Rove KO Trabulsi EJ Qian JQ Drewnowska KP et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: Prospective study of 1 962 Cases. J Urol 2012; 188: 1726-31
9. Ng CF Yeung R Chiu PK Lam NY Chow J et al. The role of urine prostate cancer antigen 3 mRNA levels in the diagnosis of prostate cancer among Hong Kong Chinese patients. Hong Kong Med J 2012; 18: 459-65
10. Ochiai A Okihara K Kamoi K Oikawa T Shimazui T et al. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy. BJU Int 2013; 111: 928-33
11. Salagierski M Mulders P Schalken JA. Predicting prostate biopsy outcome using a PCA3-based nomogram in a polish cohort. Anticancer Res 2013; 33: 553-8
12. Pepe P Aragona F. Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-finding protocol. Can J Urol 2013; 20: 6620-4
13. Goode RR Marshall SJ Duff M Chevli E Chevli KK. Use of PCA3 in Detecting prostate cancer in initial and repeat prostate biopsy patients. Prostate 2013; 73: 48-53
14. Wu AK Reese AC Cooperberg MR Sadetsky N Shinohara K. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer. Prostate Cancer Prostatic Dis 2012; 15: 100-5
15. Pepe P Fraggetta F Galia A Skonieczny G Aragona F. PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35?. Int Braz J Urol 2012; 38: 489-95
16. Bollito E De Luca S Cicilano M Passera R Grande S et al. Prostate cancer gene 3 urine assay cutoff in Diagnosis of prostate cancer: Validation study on an Italian patient population undergoing first and repeat biopsy. Anal Quant Cytol Histol 2012; 34: 96-104
17. Barbera M Pepe P Paola Q Aragona F. PCA3 score accuracy in Diagnosing prostate cancer at repeat biopsy: Our experience in 177 patients Arch Ital Urol Androl 2012; 84: 227-9
18. Auprich M Augustin H Budaus L Kluth L Mannweiler S et al. A comparative performance analysis of total prostate-specific antigen percentage free prostate-specific antigen prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first second and third repeat prostate biopsy. BJU Int 2012; 109: 1627-35
19. Pepe P Aragona F. PCA3 score vs PSA free/total accuracy in prostate cancer diagnosis at repeat saturation biopsy. Anticancer Res 2011; 31: 4445-9
20. Remzi M Haese A Van Poppel H De la Taille A Stenzl A et al. Follow-up of men with an elevated PCA3 score and a negative biopsy: Does an elevated PCA3 score indeed predict the presence of prostate cancer?. BJU Int 2010; 106: 1138-42
21. Aubin SMJ Reid J Sarno MJ Blase A Aussie J et al. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: Validation in the placebo arm of the dutasteride REDUCE trial. J Urol 2010; 184: 1947-52
22. Haese A de la Taille A van Poppel H Marberger M Stenzl A et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54: 1081-8
23. Fradet Y Saad F Aprikian A Dessureault J Elhilali M et al. uPM3 a new molecular urine test for the detection of prostate cancer. Urology 2004; 64: 311-5
24. Tinzl M Marberger M Horvath S Chypre C. DD3PCA3 RNA analysis in urine: New perspective for detecting prostate cancer. Eur Urol 2004; 46: 182-6
25. Tombal B Andriole GL de la Taille A Gontero P Haese A et al. Clinical judgment versus biomarker prostate cancer gene 3: Which is best when Determining the need for repeat prostate biopsy?. Urology 2013; 81: 998-1004
26. Deras IL Aubin SM Blase A Day JR Koo S et al. PCA3: Molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179:1587-92
27. Murata M Watanabe M Yamanaka M Kubota Y Ito H et al. Genetic polymorphisms in cytochrome P450 (CYP) 1A1 CYP1A2 CYP2E1 glutathione S-Transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett 2001; 165: 171-7
28. Tsavaler L Shapero MH Morkowski S Laus R. Trp-p8 a novel prostate-specific gene is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res 2001; 61: 3760-9
29. Korkmaz KS Elbi C Korkmaz CG Loda M Hager GL et al. Molecular cloning and characterization of STAMP1 a highly prostate-specific six transmembrane protein that is overexpressed in prostate cancer. J Biol Chem 2002; 277: 36689-96
30. Herness EA Naz RK. A novel human prostate-specific gene-1 (HPG-1) molecular cloning sequencing and its potential involvement in prostate carcinogenesis. Cancer Res 2003; 63: 329-36
31. Jiang Z Wu CL Woda BA Iczkowski KA Chu PG et al. Alpha-methylacyl-CoA racemase: Multi-institutional study of a new prostate cancer marker. Histopathology 2004; 45: 218-25
32. Korkmaz CG Korkmaz KS Kurys P Elbi C Wang L et al. Molecular cloning and characterization of STAMP2 an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer. Oncogene 2005; 24: 4934-45
33. Ruscica M Dozio E Boghossian S Bovo G Martos RiÄ. V et al. Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells. Endocrinology 2006; 147: 1466-73
34. Yang J Gao W Song NH Wang W Zhang JX et al. The risks degree of malignancy and clinical progression of prostate cancer associated with the MDM2 T309G polymorphism: Meta-Analysis Asian J Androl 2012; 14: 726-31
35. Ribarska T Bastian KM Koch A Schulz WA. Specific changes in the expression of imprinted genes in prostate cancer: Implications for cancer progression and epigenetic regulation. Asian J Androl 2012; 14: 436-50
36. Walia G Sun Y Soule HR. Global advances in prostate cancer diagnosis and therapy. Asian J Androl 2013; 15: 299-300
37. Tricoli JV Schoenfeldt M Conley BA. Detection of prostate cancer and predicting progression: Current and future diagnostic markers. Clin Cancer Res 2004; 10: 3943-53
38. Groskopf J Aubin SM Deras IL Blase A Bodrug S et al. APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 52: 1089-95
39. Marks LS Fradet Y Deras IL Blase A Mathis J et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007; 69: 532-5.